<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Azithromycin and clarithromycin
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Azithromycin and clarithromycin
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Azithromycin and clarithromycin
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amy L Graziani, PharmD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David C Hooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 12, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         are derivatives of the older macrolide antibiotic
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         . They are used in the treatment of a variety of infections, including community-acquired respiratory tract infections and mycobacterial infections. The structural modifications made to erythromycin significantly changed the spectrum of activity, dosing, and administration of these newer agents.
        </p>
        <p>
         The spectrum of activity, mechanisms of action and resistance, pharmacokinetics, interactions with other drugs, and adverse effects of these newer macrolide antibiotics will be reviewed here. The use of these drugs for community-acquired pneumonia and coronavirus disease 2019 (COVID-19) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">
          "Treatment of community-acquired pneumonia in adults in the outpatient setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">
          "COVID-19: Management of adults with acute illness in the outpatient setting"
         </a>
         .)
        </p>
        <p>
         The macrolides are sometimes used for their anti-inflammatory effects. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Treatment of BOS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4366.html" rel="external">
          "Diffuse panbronchiolitis", section on 'Macrolide antibiotics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MECHANISM OF ACTION AND CHEMICAL STRUCTURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antibacterial mechanism of action of the newer macrolides is similar to that of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         . They bind to the 50S subunit of bacterial ribosomes, leading to inhibition of transpeptidation, translocation, chain elongation, and, ultimately, bacterial protein synthesis [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         has the same macrolide 14-membered lactone ring as
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ; the only difference is that, at position six, a methoxy group replaces the hydroxyl group [
         <a href="#rid1">
          1
         </a>
         ].
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         , in comparison, has a 15-membered ring and a methyl-substituted nitrogen replacing the 9A carbonyl group. For this reason, azithromycin is more precisely referred to as an azalide rather than a macrolide [
         <a href="#rid2">
          2-4
         </a>
         ].
        </p>
        <p>
         These structural changes have made the newer macrolides more acid stable than
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , providing improved oral absorption, tolerance, and pharmacokinetic properties. The newer macrolides also have a broader spectrum of antibacterial activity than erythromycin [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          SPECTRUM OF ACTIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         have a broader spectrum of activity than
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         that includes many gram-negative, atypical, and mycobacterial organisms as well as gram-positive organisms. These agents are therefore used in a variety of infections including infections of the respiratory tract, mycobacterial infections, and sexually transmitted diseases [
         <a href="#rid5">
          5-9
         </a>
         ].
        </p>
        <p>
         While
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         are active against the above organisms, they may not be the preferred treatment in all cases. When treating such infections, the susceptibility of the organism should be confirmed when possible. It is also important to note that these macrolides are often used as part of a treatment regimen and not as single agents (eg, for the treatment of mycobacterial diseases).
        </p>
        <p class="headingAnchor" id="H2017345490">
         <span class="h2">
          Azithromycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is active against many gram-positive organisms, including erythromycin-susceptible
         <em>
          Streptococcus pneumoniae
         </em>
         , Group A, B, C, and G streptococcus, and methicillin-susceptible
         <em>
          Staphylococcus aureus
         </em>
         [
         <a href="#rid10">
          10
         </a>
         ]. Compared with
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , azithromycin has expanded activity against susceptible gram-negative organisms, including
         <em>
          Haemophilus spp, Moraxella catarrhalis, Escherichia coli, Salmonella spp, Yersinia enterocolitica, Shigella spp, Campylobacter jejuni, Vibrio cholerae, Neisseria gonorrhoeae, Helicobacter pylori, and Bordetella pertussis
         </em>
         .
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is also active against several atypical organisms including
         <em>
          Mycoplasma pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae, Babesia microti, and Ureaplasma spp
         </em>
         [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Due to its activity against Mycoplasma genitalium, Haemophilus ducreyi (Chancroid),
         <em>
          Klebsiella granulomatis
         </em>
         (granuloma inguinale),
         <em>
          Chlamydia trachomatis, and Neisseria gonorrhoeae
         </em>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         is also used in the treatment of sexually transmitted infections (STIs) [
         <a href="#rid7">
          7,9
         </a>
         ].
        </p>
        <p>
         Due to its activity against non-tuberculous mycobacteria,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         is used as a primary part of treatment regimens for
         <em>
          Mycobacterium avium
         </em>
         complex infections and may also be used in treatment regimens for
         <em>
          Mycobacterium abscessus
         </em>
         infections, if susceptibility is confirmed (see
         <a class="medical medical_review" href="/z/d/html/3755.html" rel="external">
          "Mycobacterium avium complex (MAC) infections in persons with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         ), and other rapidly growing mycobacterial infections:
         <em>
          M. chelonae
         </em>
         and
         <em>
          M. fortuitum
         </em>
         [
         <a href="#rid5">
          5,12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">
          "Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         use has also been reported in the treatment of select
         <em>
          Pseudomonas aeruginosa
         </em>
         infections. The mechanism of action for this organism is not definitively known but may be related to suppression of the inflammatory response, biofilm, and/or direct antibacterial effects [
         <a href="#rid13">
          13
         </a>
         ]. The use of azithromycin for pseudomonal infections in patients with cystic fibrosis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2160032557">
         <span class="h2">
          Clarithromycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         and it’s active metabolite 14-hydroxyclarithromycin have a similar spectrum of activity to
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , with broad gram-positive, gram-negative, atypical, and antimycobacterial activity [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         is somewhat more active than
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         in vitro against wildtype
         <em>
          S. pneumoniae
         </em>
         and has similar activity against
         <em>
          M. pneumoniae
         </em>
         ,
         <em>
          C. pneumoniae
         </em>
         , and
         <em>
          Legionella pneumophilia
         </em>
         [
         <a href="#rid10">
          10
         </a>
         ].
         <em>
         </em>
         Like azithromycin, clarithromycin has activity against
         <em>
          Ureaplasma urealyticum and B. pertussis.
         </em>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         is generally not used for STIs because it is less active than
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         against some organisms (M. genitalium
         <em>
          ) and because the pharmacokinetics and tolerance favor azithromycin
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/7579.html" rel="external">
          "Treatment of
          <i>
           Chlamydia trachomatis
          </i>
          infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7592.html" rel="external">
          "Approach to the patient with genital ulcers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2853599975">
         <span class="h1">
          RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mechanisms of resistance to
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         are the same as or similar to those of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         . Alterations in ribosomal ribonucleic acid (RNA) can confer complete cross-resistance among erythromycin, azithromycin, and clarithromycin in gram-positive organisms.
        </p>
        <p>
         Acquired macrolide resistance is an increasing problem. As with resistance to other drugs, antibiotic use has been associated with development of resistance. This relationship was directly demonstrated in a randomized double-blind trial in which 224 healthy volunteers were assigned to
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , or placebo; the end point was the development of pharyngeal carriage of macrolide-resistant streptococci [
         <a href="#rid14">
          14
         </a>
         ]. The proportion of macrolide-resistant streptococci was 26 to 30 percent at baseline. Both macrolides significantly increased the proportion of macrolide-resistant streptococci compared with placebo, peaking at day 4 to 8, with a mean increase of about 50 percent (to an absolute proportion of over 80 percent) compared with a 4 percent increase with placebo. The increase in resistance was greater with azithromycin, a possible reflection of its much longer half-life. Clarithromycin resistance among
         <em>
          M. avium
         </em>
         complex and
         <em>
          M. abscessus
         </em>
         has also been reported [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
         Two main mechanisms of acquired macrolide resistance have been described [
         <a href="#rid17">
          17-19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methylases encoded by the acquired
         <em>
          erm
         </em>
         (
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ribosome methylase) genes (
         <em>
          ermA
         </em>
         ,
         <em>
          ermB
         </em>
         ,
         <em>
          ermC
         </em>
         ) alter the macrolide-binding site on the bacterial ribosomal RNA, usually conferring a high degree of macrolide resistance [
         <a href="#rid20">
          20
         </a>
         ]. In a study of selected resistance in volunteers,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         but not
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         selected for this type of resistance [
         <a href="#rid14">
          14
         </a>
         ]. This mechanism usually also confers resistance to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active macrolide efflux pumps, encoded by the
         <em>
          mef
         </em>
         (macrolide efflux)
         <em>
          msrA
         </em>
         and
         <em>
          msrB
         </em>
         genes, confer a low to moderate degree of macrolide resistance [
         <a href="#rid20">
          20-22
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In North America, efflux pump resistance mechanisms are more common, whereas the ribosomal modification mechanism is more common in Europe [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         These mechanisms are both due to acquired genes and are responsible for
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         resistance in most gram-positive cocci (eg,
         <em>
          S. aureus
         </em>
         ,
         <em>
          S. pneumoniae
         </em>
         , other streptococci). (See
         <a class="medical medical_review" href="/z/d/html/7033.html" rel="external">
          "Resistance of
          <i>
           Streptococcus pneumoniae
          </i>
          to the macrolides, azalides, and lincosamides"
         </a>
         .)
        </p>
        <p>
         In contrast with the mechanisms of acquired resistance, intrinsic resistance exhibited by Enterobacterales,
         <em>
          Pseudomonas
         </em>
         spp, and
         <em>
          Acinetobacter
         </em>
         spp is due to decreased permeability of the outer cell envelope. Resistance to macrolides due to mutation of native chromosomal genes is uncommon because many bacteria have multiple copies of the ribosomal RNA genes that encode the macrolide-binding sites on the ribosome, and mutations of multiple gene copies are infrequent. Mycobacteria are an exception. Because they have a single chromosomal copy of the ribosomal RNA gene, selection of mutational resistance can occur readily.
        </p>
        <p>
         M. abscessus and M. fortuitum organisms have a clinically important inducible macrolide-resistance gene (erm) that may not be detected on routine susceptibility testing [
         <a href="#rid24">
          24-26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria"
         </a>
         .)
        </p>
        <p>
         Increasing resistance to
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         has been described in patients with syphilis, and it is therefore generally not recommended for this infection; the frequency of resistance varies with geographic area [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">
          "Syphilis: Treatment and monitoring"
         </a>
         .)
        </p>
        <p>
         Despite relatively high rates of in vitro macrolide-resistant
         <em>
          S. pneumoniae
         </em>
         , studies of hospitalized patients with community-acquired pneumonia (CAP) have shown improved outcomes when macrolides are included in combination antibiotic regimens. Macrolides have immunomodulatory and antiinflammatory effects that reduce interleukin 8 and tumor necrosis factor-alpha, which may in part explain the benefit [
         <a href="#rid28">
          28-30
         </a>
         ]. The use of macrolides as part of a combination regimen for the treatment of CAP in hospitalized patients is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          METABOLISM AND PHARMACOKINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         have improved oral absorption, longer serum half-lives, and better tissue and intracellular penetration than
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         .
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Acid stability and food
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         are stable at gastric pH. As a result, their bioavailability is better than that of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         base (25 percent), and enteric coating is not required. The immediate-release tablet formulations and oral suspensions can be taken with or without food [
         <a href="#rid1">
          1,4,31
         </a>
         ]. In contrast, azithromycin extended-release suspension should be taken on an empty stomach, and clarithromycin extended-release tablets should be administered with food.
        </p>
        <p>
         The bioavailability of oral
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         tablets is 37 percent [
         <a href="#rid32">
          32
         </a>
         ]. Despite this, serum concentrations are quite low, due to wide tissue distribution and high intracellular concentrations [
         <a href="#rid33">
          33
         </a>
         ]. A regimen of 500 mg on day 1 followed by 250 mg/day for nine days leads to an average plasma azithromycin concentration of 0.21 mcg/mL [
         <a href="#rid2">
          2-4,34,35
         </a>
         ]. The oral bioavailability of the
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         immediate-release tablets (dosed every 12 hours) is approximately 50 percent; the mean steady-state peak serum concentration following 500 mg orally every 12 hours is 2 to 3 mcg/mL [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Tissue and intracellular penetration
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         penetrate well into most tissues and fluids, which correlates with their clinical efficacy in a variety of infection sites [
         <a href="#rid10">
          10
         </a>
         ]. Because these antibiotics also concentrate in tissues, epithelial lining fluid and alveolar macrophage concentrations are usually higher than plasma levels [
         <a href="#rid1">
          1,4
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         concentrates in tissues to a greater extent than
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         (and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ) [
         <a href="#rid1">
          1,36
         </a>
         ]. Levels in sputum and lung are 10 to 100 times those in the plasma; alveolar macrophage and neutrophil concentrations are also higher [
         <a href="#rid2">
          2,4,36
         </a>
         ]. In comparison, clarithromycin levels in the lung are only six to eight times higher than the plasma concentration [
         <a href="#rid35">
          35
         </a>
         ]. These differences in intracellular penetration and plasma concentration make comparison of the activity of these agents by traditional, in vitro methods (such as minimum inhibitory concentration) difficult. The clinical significance of the better tissue penetration but lower plasma levels of azithromycin is not definitively known. High levels of azithromycin persist in tissues for extended periods, which is beneficial for dosing regimens and adherence, but may facilitate selection for the resistance seen with the agent.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Active metabolites
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is excreted in the bile and then the feces, with very little unchanged drug appearing in the urine [
         <a href="#rid2">
          2,4
         </a>
         ]. Several azithromycin metabolites have been identified, but none is known to be biologically active [
         <a href="#rid4">
          4,37
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         is hydroxylated, N-demethylated, and hydrolyzed in the liver, utilizing the cytochrome P450 enzyme system. The major metabolite, 14-hydroxy-clarithromycin, is microbiologically active [
         <a href="#rid1">
          1,2
         </a>
         ], and it is more active than the parent compound against some species. As an example, among
         <em>
          H. influenzae
         </em>
         isolates from patients with community-acquired pneumonia, the concentration at which 90 percent of organisms are inhibited (MIC
         <sub>
          90
         </sub>
         ) of the 14-OH metabolite was 3 mcg/mL compared with 9 mcg/mL for the parent compound [
         <a href="#rid38">
          38
         </a>
         ]. This active clarithromycin metabolite is another variable that makes a comparison between clarithromycin and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         difficult in vitro. Twenty to 30 percent of clarithromycin is excreted unchanged in the urine [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DOSING AND ADMINISTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         is typically given for a shorter period because of the long intracellular half-life (40 to 68 hours) and slow release from tissue sites. Thus, for many infections, a once-daily 5-day regimen is as effective as 10-day courses of the other macrolides.
        </p>
        <p>
         The 2 g extended-release oral suspension of
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         (Zmax) has an even shorter regimen, as it is given as a single dose due to its long half-life [
         <a href="#rid40">
          40
         </a>
         ]. Unlike azithromycin tablets and immediate-release suspension, the extended-release suspension should be taken one hour before or two hours after food. It must be consumed within 12 hours of being reconstituted.
        </p>
        <p>
         Additional information on dosing and administration can be found in the Lexicomp drug monographs. (See
         <a class="drug drug_general" href="/z/d/drug information/8868.html" rel="external">
          "Azithromycin (systemic): Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/9273.html" rel="external">
          "Clarithromycin: Drug information"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Renal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         dosing does not require adjustment with decreased creatinine clearance. In patients with a creatinine clearance below 30 mL/minute, the dose of
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         should be reduced by half or the dosing interval should be doubled.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although we have the most experience in pregnant females with
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         is now the most used macrolide in pregnant females.
        </p>
        <p>
         Some studies have shown a potential association between macrolide use during pregnancy and congenital anomalies or other adverse outcomes [
         <a href="#rid41">
          41-43
         </a>
         ], while other studies have not [
         <a href="#rid44">
          44-48
         </a>
         ]. Additional research is needed to evaluate azithromycin- and clarithromycin-specific exposures and risks and potential confounding factors, including indication, trimester, dose, and follow-up.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Azithromycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is commonly used in pregnancy, although its safety, particularly during the first trimester, is unclear. While some studies suggest that azithromycin may be associated with congenital anomalies, this association is not consistently seen across studies and it is uncertain if the association is causal [
         <a href="#rid37">
          37,49
         </a>
         ].
        </p>
        <p>
         In one population-based cohort study evaluating over 100,000 children for a median of 5.8 years following birth, maternal
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         use during first trimester was associated with an increased risk of major medical malformations when compared with penicillin (adjusted risk ratio 1.55, 95% CI 1.19-2.03) [
         <a href="#rid41">
          41
         </a>
         ]. However, results were not controlled for antibiotic indication. In two other studies, patients with cervical chlamydial infection received a 1 g dose of azithromycin and were followed for efficacy and toxicity [
         <a href="#rid44">
          44,45
         </a>
         ]. Teratogenic effects were not noted, although it is not clear if neonatal examination and follow-up were required. In another study, 123 pregnant women taking azithromycin were prospectively followed along with two groups of matched controls [
         <a href="#rid46">
          46
         </a>
         ]. The incidence of major malformations was similar in the azithromycin-exposed and -unexposed groups and was not more than the 1 to 3 percent that would be expected in the general population. However, all three of the malformations occurred in the infants of mothers who received five days of azithromycin for upper respiratory tract infections and the study was underpowered to detect a difference between the azithromycin-exposed and -unexposed groups.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Clarithromycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         should not be used in pregnant females except in circumstances in which no alternative therapy is appropriate [
         <a href="#rid50">
          50
         </a>
         ]. No adequate and well-controlled trials in pregnant females have been performed but teratogenic effects (including cleft palate, cardiovascular anomalies, and fetal growth restriction) have occurred in monkeys, rats, mice, and rabbits with plasma clarithromycin concentrations 2 to 17 times the levels normally achieved in humans.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          ADVERSE REACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , like
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         have been associated with gastrointestinal (GI) side effects, hepatoxicity, QT prolongation, and other cardiovascular events. Among these agents, azithromycin is generally most well tolerated, followed by clarithromycin and erythromycin.
        </p>
        <p>
         The following provides a brief summary of some of the major adverse effects associated with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         . Details about specific adverse effects or interactions may be obtained by using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Hepatotoxicity
         </span>
        </p>
        <p class="headingAnchor" id="H264150671">
         <span class="h3">
          Azithromycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postmarketing reports have identified various hepatic abnormalities in patients receiving
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , including abnormal liver function tests, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure; some of these cases have resulted in death [
         <a href="#rid51">
          51,52
         </a>
         ]. Azithromycin is therefore contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use. It should be discontinued immediately if signs or symptoms of hepatitis occur.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Gastrointestinal toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         are better tolerated than
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , which may in part be related to the greater stability of the drugs and the lack of formation of the anhydrohemiketal degradation product thought to be responsible for some of the GI side effects associated with erythromycin [
         <a href="#rid35">
          35,53
         </a>
         ]. Nonetheless, GI side effects remain common causes of discontinuation of azithromycin and clarithromycin. Rates of nausea, vomiting, diarrhea, and abdominal pain are generally 1 to 14 percent, but nausea rates as high as 28 percent have been reported with clarithromycin [
         <a href="#rid8">
          8,54
         </a>
         ]. Abdominal cramping with subsequent loose stools is common with high doses of oral azithromycin [
         <a href="#rid4">
          4,35
         </a>
         ] and may be related to stimulation of motilin. Azithromycin and clarithromycin, like erythromycin, have a dose-related effect on motilin receptors and can thereby stimulate the smooth muscle of the gastrointestinal tract. In fact, these drugs have been used clinically to stimulate gastric motility [
         <a href="#rid55">
          55-58
         </a>
         ].
        </p>
        <p>
         The intravenous formulation of
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         also causes gastrointestinal side effects including nausea (4 to 7 percent), vomiting (1.4 percent), diarrhea (4 to 9 percent), and abdominal pain (2 to 3 percent).
        </p>
        <p>
         Patients can often tolerate these GI side effects and complete the treatment course. When that is not the case, and when appropriate clinically and feasible without reducing efficacy or adherence, we may try to reduce the dose or split the daily dose into smaller increments (eg,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         600 mg twice a day once weekly rather than 1200 mg as a single dose once weekly) for
         <em>
          M.
         </em>
         <em>
          avium
         </em>
         complex prophylaxis) [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Intolerance due to these GI symptoms with one drug does not necessarily predict intolerance to the other. Some patients, for example, have intolerable side effects with
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         but not
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , and vice versa.
        </p>
        <p>
         Dysgeusia, on the other hand, is a relatively frequent complaint in patients who are treated with
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         but is rare with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         . If a dose reduction or change to azithromycin is not clinically appropriate, masking the taste with gum, hard candy, or ice chips can be attempted, although this usually does not reduce symptoms significantly.
        </p>
        <p class="headingAnchor" id="H139392462">
         <span class="h2">
          QT interval prolongation and cardiovascular events
         </span>
         <span class="headingEndMark">
          —
         </span>
         All macrolides have been associated with QT interval prolongation [
         <a href="#rid60">
          60-68
         </a>
         ]. Before giving one of these agents, it is important for clinicians to determine if a patient is at risk for torsades de pointes (eg, history of a long QT interval, taking other medications that can prolong the QT interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 1
         </a>
         ), drug interactions, older age, electrolyte abnormalities) [
         <a href="#rid69">
          69
         </a>
         ]. While it is prudent for clinicians to assess the risk of torsades de pointes when considering a macrolide for patients at risk for cardiovascular events [
         <a href="#rid70">
          70
         </a>
         ], the potential for alternative antibiotics, including
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         , to prolong the QT interval must also be considered. Similarly, the potential benefit seen in patients taking macrolides for certain indications should also be considered [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Incidence'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'QT interval prolongation'
         </a>
         .)
        </p>
        <p>
         Macrolides have also been associated with increased cardiovascular and all-cause mortality [
         <a href="#rid65">
          65,72-78
         </a>
         ]. However, this association has not been consistently demonstrated across studies [
         <a href="#rid71">
          71,73,79-83
         </a>
         ]. Discrepancies among studies may be due to differences in patient populations (eg, age, presence of underlying cardiovascular disease, or certain P-glycoprotein polymorphisms), the severity of infections being treated, study methodologies, and other variables [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         Because of potential for adverse cardiac events, the US Food and Drug Administration (FDA) has issued warnings about the use of
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 2013, the FDA issued a warning about the risk of QT interval prolongation and potentially fatal torsades de pointes among patients taking
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         [
         <a href="#rid70">
          70
         </a>
         ]. The warning is based on a retrospective cohort study that showed that patients taking a five-day course of azithromycin had an increased risk of cardiovascular mortality (hazard ratio [HR] 2.88, 95% CI 1.79-4.63) and all-cause mortality (HR 1.85, 95% CI 1.25-2.75) when compared with propensity-matched controls who did not receive antibiotics [
         <a href="#rid85">
          85
         </a>
         ]. The risk of cardiovascular death was also greater than that observed in propensity-matched controls taking either
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ; a nonstatistically significant increased risk was detected when comparing azithromycin with
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         . Overall, the degree of risk appeared to be higher in patients with known cardiovascular disease and correlated with underlying disease severity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 2017, the FDA issued a warning about increased mortality risk among patients with coronary artery disease who were taking
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         [
         <a href="#rid50">
          50,86
         </a>
         ]. The warning is based on a 10-year follow-up study of a randomized trial evaluating 4373 patients with stable coronary heart disease who received either clarithromycin or placebo for the treatment of atherosclerosis [
         <a href="#rid74">
          74,87
         </a>
         ]. Patients who received clarithromycin had an increased risk of all-cause mortality (HR 1.10, 95% CI 1.02-1.38) over a 10-year period and increased risk of cardiovascular mortality during the first three years of follow-up (HR 1.42, 95% CI 1.09-1.84). In addition, some [
         <a href="#rid62">
          62,63,74,88,89
         </a>
         ] but not all [
         <a href="#rid75">
          75,90
         </a>
         ] epidemiologic studies evaluating clarithromycin for the treatment of underlying bacterial infections have shown an increased risk of cardiovascular mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 2021, the FDA issued a warning about increased risk of acute cardiovascular death among all patients taking
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , especially within the first five days of use [
         <a href="#rid91">
          91
         </a>
         ]. The warning was based on observational studies [
         <a href="#rid80">
          80
         </a>
         ], including one that showed increased risk of acute cardiovascular mortality with azithromycin compared with
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         exposure (HR 1.71, 95% CI 1.06-2.76) [
         <a href="#rid78">
          78
         </a>
         ]. However, causality has not been established.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe reactions are rare but possible with any macrolide. These include anaphylaxis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), pseudomembranous colitis, and exacerbations of myasthenia gravis [
         <a href="#rid50">
          50,92
         </a>
         ]. A severe reaction to
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         may persist for several days due to its long half-life. Irreversible hearing loss has been reported with azithromycin,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         [
         <a href="#rid93">
          93-95
         </a>
         ]. Reversible hearing loss has also been reported following macrolide use, especially when they have been given at high doses [
         <a href="#rid96">
          96-99
         </a>
         ].
        </p>
        <p>
         An increased risk of cancer relapse and death was seen in hematopoietic stem cell transplant recipients who received long-term (two years)
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         for prevention of bronchiolitis obliterans [
         <a href="#rid100">
          100
         </a>
         ]. This prompted early discontinuation of the study and an August 2018 FDA safety alert recommending against long-term prophylactic azithromycin in patients with blood or lymphatic cancers [
         <a href="#rid101">
          101
         </a>
         ]. An increased rate of cancer relapse was also seen in hematopoietic stem cell transplant patients with acute lymphoblastic leukemia and acute myeloid leukemia or myelodysplastic syndrome receiving long-term azithromycin, and second neoplasms were seen in hematopoietic stem cell patients treated for bronchiolitis obliterans [
         <a href="#rid102">
          102,103
         </a>
         ]. In contrast, cancer relapse rates and death were not increased in patients who received azithromycin for treatment of established moderate to severe chronic graft-versus-host disease or in allogenic stem cell transplant patients being treated for bronchiolitis obliterans [
         <a href="#rid104">
          104,105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          DRUG INTERACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The macrolides have a variety of drug interactions, many of which are mediated by inhibition of hepatic cytochrome CYP (P450) 3A enzymes [
         <a href="#rid106">
          106
         </a>
         ]. In contrast with
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         is a much weaker inhibitor of the CYP3A4 hepatic microsomal enzyme so there are many fewer azithromycin-related, clinically significant drug-drug interactions. However, because azithromycin is a weak CYP3A4 inhibitor and a potent inhibitor of the P-glycoprotein drug transporter, clinically important drug interactions have also been reported with azithromycin, albeit less often. As examples, concomitant azithromycin may increase the risk of statin-associated rhabdomyolysis, including in patients with the heterozygous SLCO1B1 polymorphism, which decreases hepatic uptake of
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         [
         <a href="#rid107">
          107,108
         </a>
         ]. Clarithromycin was associated with a higher risk of hemorrhage than azithromycin in patients over age 66 taking the direct-acting anticoagulants,
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         ,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         , and
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         [
         <a href="#rid109">
          109
         </a>
         ]. In another study, fatalities were reported in patients receiving clarithromycin and
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         ; specific colchicine dose reduction recommendations have been published [
         <a href="#rid110">
          110,111
         </a>
         ].
        </p>
        <p>
         In a population-based retrospective cohort study of older adults (mean age 76 years), coprescribing
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         with a calcium channel blocker (compared with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         plus a calcium channel blocker) was associated with a small but statistically significant increase in risk of hospitalization with acute kidney injury (absolute risk increase 0.22 percent, 95% CI 0.16-0.27 percent) [
         <a href="#rid112">
          112
         </a>
         ]. Coprescription with clarithromycin was also associated with a higher risk of hospitalization with hypotension (absolute risk increase 0.04 percent, 95% CI 0.02-0.07 percent) and all-cause mortality (absolute risk increase 0.43 percent, 95% CI 0.35-0.51 percent). Although the risks associated with the combined use of clarithromycin and calcium channel blockers appear to be small, they should be considered when deciding whether to use these agents in combination in older patients or other patients at risk for acute kidney injury.
        </p>
        <p>
         Drug interactions that can occur as a result of additive pharmacologic effects should also be considered when prescribing macrolides. For example, both
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         and the antihistamine
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         can cause QTc prolongation. When combined for the treatment of upper respiratory tract infections, the prolongation over the first four days of therapy can be significant [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
         Details about specific interactions may be obtained by using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="headingAnchor" id="H264149919">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         −
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         are azalide and macrolide antibiotics that are used in the treatment of several infections, including community-acquired respiratory tract infections, sexually transmitted infections, and mycobacterial infections. They are derivatives of the older macrolide antibiotic
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         . (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism of action
         </strong>
         − Their mechanism of action is similar to that of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         . They bind to the 50S subunit of bacterial ribosomes, leading to inhibition of transpeptidation, translocation, chain elongation, and, ultimately, bacterial protein synthesis. (See
         <a class="local">
          'Mechanism of action and chemical structure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemical
         </strong>
         <strong>
          structure
         </strong>
         − Structural changes make
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         more acid stable than
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , providing improved oral absorption, tolerance, and pharmacokinetic properties. (See
         <a class="local">
          'Mechanism of action and chemical structure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spectrum of activity
         </strong>
         −
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         also have a broader spectrum of activity than
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         and include activity against respiratory tract pathogens such as susceptible strains of
         <em>
          Streptococcus pneumoniae
         </em>
         ,
         <em>
          Haemophilus
         </em>
         spp,
         <em>
          Moraxella catarrhalis
         </em>
         , and atypical pneumonia pathogens as well as against various other pathogens including some gram-positive and gram-negative bacteria and
         <em>
          Mycobacterium avium
         </em>
         complex. (See
         <a class="local">
          'Spectrum of activity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibiotic resistance mechanisms
         </strong>
         − Two main mechanisms of acquired macrolide resistance have been described:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Methylases encoded by the
         <em>
          erm
         </em>
         (
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ribosome methylase) genes (
         <em>
          ermA
         </em>
         ,
         <em>
          ermB
         </em>
         ,
         <em>
          ermC
         </em>
         ) alter the macrolide-binding site on the bacterial ribosomal RNA, usually conferring a high degree of macrolide resistance as well as resistance to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Active macrolide efflux pumps, encoded by the
         <em>
          mef
         </em>
         (macrolide efflux)
         <em>
          msrA
         </em>
         and
         <em>
          msrB
         </em>
         genes, confer a low to moderate degree of macrolide resistance. These mechanisms are responsible for
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         resistance in most gram-positive cocci (eg,
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          S. pneumoniae
         </em>
         , other streptococci). In contrast with the mechanisms of acquired resistance, intrinsic resistance exhibited by Enterobacterales,
         <em>
          Pseudomonas
         </em>
         spp, and
         <em>
          Acinetobacter
         </em>
         spp is due to decreased permeability of the outer cell envelope. (See
         <a class="local">
          'Resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use in pregnancy
         </strong>
         −
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is commonly used in pregnancy, although its safety, particularly during the first trimester, is unclear. Some but not all observational studies suggest azithromycin may be associated with congenital anomalies, however, it is uncertain if this association is causal.
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         should not be used in pregnant females except in circumstances in which no alternative therapy is appropriate. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse reactions
         </strong>
         − Multiple adverse events have been associated with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         . Gastrointestinal intolerance is common and substantially more pronounced with clarithromycin. Both agents can cause QT prolongation, and each has been associated with cardiovascular events, though causality is not determined. Additional adverse events, including exacerbation of myasthenia gravis and hearing loss, are detailed above. (See
         <a class="local">
          'Adverse reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug interactions
         </strong>
         −
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         have a variety of drug-drug interactions, many of which are mediated by inhibition of hepatic cytochrome CYP (P450) 3A enzymes and P-glycoprotein. In contrast with clarithromycin and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , azithromycin is a weak hepatic cytochrome P450 enzyme inhibitor, leading to fewer documented drug interactions (see
         <a class="local">
          'Drug interactions'
         </a>
         above). Specific interactions with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interaction program
         </a>
         included with UpToDate.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992; 26:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapp RP, McCraney SA, Goodman NL, Shaddick DJ. New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis. Ann Pharmacother 1994; 28:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neu HC. New macrolide antibiotics: azithromycin and clarithromycin. Ann Intern Med 1992; 116:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992; 26:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           St Cyr S, Barbee L, Workowski KA, et al. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004; 18:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson RJ. In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections. Infect Drug Resist 2019; 12:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viscardi RM, Terrin ML, Magder LS, et al. Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants. Arch Dis Child Fetal Neonatal Ed 2020; 105:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SY, Moon SM, Jhun BW, et al. Species Distribution and Macrolide Susceptibility of Mycobacterium fortuitum Complex Clinical Isolates. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulloa ER, Sakoulas G. Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment for Pseudomonas aeruginosa Infections. Antibiotics (Basel) 2022; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mougari F, Bouziane F, Crockett F, et al. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson J. Acquired clarithromycin resistance in disseminated Mycobacterium avium-intracellulare complex: Case report. Reactions 2017; 1633:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corso A, Severina EP, Petruk VF, et al. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999; 29:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cetin ES, Gunes H, Kaya S, et al. Distribution of genes encoding resistance to macrolides, lincosamides and streptogramins among clinical staphylococcal isolates in a Turkish university hospital. J Microbiol Immunol Infect 2010; 43:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aktas Z, Aridogan A, Kayacan CB, Aydin D. Resistance to macrolide, lincosamide and streptogramin antibiotics in staphylococci isolated in Istanbul, Turkey. J Microbiol 2007; 45:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lina G, Quaglia A, Reverdy ME, et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999; 43:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niederman MS. Macrolide-Resistant Pneumococcus in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy? Am J Respir Crit Care Med 2015; 191:1216.
          </a>
         </li>
         <li class="breakAll">
          Philley JV, Griffith DE. Disease caused by Mycobacterium abscessus and other rapidly growing mycobacteria (RGM). In: Nontuberculous Mycobacterial Disease, Griffith D (Ed), Humana Press, New York, NY 2019.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez AA, Singer JP, Schwartz BS, et al. Management and clinical outcomes after lung transplantation in patients with pre-transplant Mycobacterium abscessus infection: A single center experience. Transpl Infect Dis 2019; 21:e13084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffith DE. Mycobacterium abscessus and Antibiotic Resistance: Same As It Ever Was. Clin Infect Dis 2019; 69:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamm LV. Global challenge of antibiotic-resistant Treponema pallidum. Antimicrob Agents Chemother 2010; 54:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cramer CL, Patterson A, Alchakaki A, Soubani AO. Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgrad Med 2017; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           File TM. Telithromycin new product overview. J Allergy Clin Immunol 2005; 115:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simicevic VN, Erceg D, Dohoczky C, et al. Lack of Effect of Food on the Bioavailability of Oral Azithromycin Tablets. Clin Drug Investig 1998; 16:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matzneller P, Krasniqi S, Kinzig M, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother 2013; 57:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992; 26:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11:137.
          </a>
         </li>
         <li class="breakAll">
          Sivapalasingam S, Steigbigel NH. Macrolides, clindamycin, and ketolides. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.396.
         </li>
         <li class="breakAll">
          Product Information for Zithromax, Biaxin, Physicians' Desk Reference, 1995.
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17:828.
          </a>
         </li>
         <li class="breakAll">
          Brater DC. Pocket Manual of Drug Use in Clinical Medicine, 6th ed, Improved Therapeutics, Indianapolis 1994.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azithromycin extended-release (Zmax) for sinusitis and pneumonia. Med Lett Drugs Ther 2005; 47:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ 2020; 368:m331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: A systematic review and meta-analysis. PLoS One 2019; 14:e0212212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leke AZ, Dolk H, Loane M, et al. Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study. Reprod Toxicol 2021; 100:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush MR, Rosa C. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet Gynecol 1994; 84:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adair CD, Gunter M, Stovall TG, et al. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. Obstet Gynecol 1998; 91:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarkar M, Woodland C, Koren G, Einarson AR. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006; 6:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ 2021; 372:n107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 2000; 9:549.
          </a>
         </li>
         <li class="breakAll">
          Briggs GG, Freeman RK, Yaffe SJ. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation, 4th ed, Williams &amp; Wilkins, Baltimore 1994. p.335.
         </li>
         <li class="breakAll">
          Clarithromcyin. United States Prescribing Information. Revised May 2016. US Food &amp; Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050662s054,050698s033,050775s002lbl.pdf (Accessed on April 10, 2017).
         </li>
         <li class="breakAll">
          Zithromax (azithromycin) tablet, single-dose packet, IV for injection, and oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm225814.htm (Accessed on March 21, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 2015; 13:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed MD, Blumer JL. Azithromycin: a critical review of the first azilide antibiotic and its role in pediatric practice. Pediatr Infect Dis J 1997; 16:1069.
          </a>
         </li>
         <li class="breakAll">
          Biaxin filmtab (clarithromycin), prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050662s048,050698s029,050775s018lbl.pdf (Accessed on April 24, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 2007; 356:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, et al. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014; 143:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deloose E, Verbeure W, Depoortere I, Tack J. Motilin: from gastric motility stimulation to hunger signalling. Nat Rev Endocrinol 2019; 15:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sancak S, Gursoy T, Tuten A, et al. A pioneering study: oral clarithromycin treatment for feeding intolerance in very low birth weight preterm infants. J Matern Fetal Neonatal Med 2018; 31:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. Am J Med 2018; 131:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002; 303:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002; 302:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013; 346:f1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svanström H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ 2014; 349:g4930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamochi H, Nii T, Eguchi K, et al. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999; 63:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng YJ, Nie XY, Chen XM, et al. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. J Am Coll Cardiol 2015; 66:2173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramireddy A, Chugh H, Reinier K, et al. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc 2020; 9:e017144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connell TF, Bradley CJ, Abbas AE, et al. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. JACC Clin Electrophysiol 2021; 7:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol 2016; 67:1639.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Azithromycin (Zithromax or Zmax): Drug safety communication - risk of potentially fatal heart rhythms. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm343350.htm?source=govdelivery (Accessed on March 15, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trac MH, McArthur E, Jandoc R, et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ 2016; 188:E120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosholder AD, Mathew J, Alexander JJ, et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013; 368:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hancox JC, Hasnain M, Vieweg WV, et al. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Ther Adv Infect Dis 2013; 1:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkel P, Hilden J, Hansen JF, et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol 2015; 182:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou HW, Wang JL, Chang CH, et al. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis 2015; 60:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu ZK, Yuan J, Li M, et al. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf 2015; 14:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014; 12:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaroff JG, Cheetham TC, Palmetto N, et al. Association of Azithromycin Use With Cardiovascular Mortality. JAMA Netw Open 2020; 3:e208199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trifiro G, de Ridder M, Sultana J, et al. Use of azithromycin and risk of ventricular arrhythmia. CMAJ 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368:1704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014; 311:2199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khosropour CM, Capizzi JD, Schafer SD, et al. Lack of association between azithromycin and death from cardiovascular causes. N Engl J Med 2014; 370:1961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorelik E, Masarwa R, Perlman A, et al. Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mordi IR, Chan BK, Yanez ND, et al. Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK. PLoS Med 2020; 17:e1003372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voelker R. Another Caution for Clarithromycin. JAMA 2018; 319:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong AY, Root A, Douglas IJ, et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016; 352:h6926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosholder AD, Lee JY, Zhou EH, et al. Long-Term Risk of Acute Myocardial Infarction, Stroke, and Death With Outpatient Use of Clarithromycin: A Retrospective Cohort Study. Am J Epidemiol 2018; 187:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berni E, de Voogd H, Halcox JP, et al. Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. BMJ Open 2017; 7:e013398.
          </a>
         </li>
         <li class="breakAll">
          United States Food and Drug Administration. Supplemental Approval Letter. November 2021. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/050693Orig1s034;050730Orig1s043ltr.pdf (Accessed on June 15, 2022).
         </li>
         <li class="breakAll">
          Zithromax (azithromycin). United States Prescribing Information. Revised March 2017. US Food &amp; Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050670s032,050710s046,050711s043,050784s030lbl.pdf (Accessed on April 10, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ress BD, Gross EM. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol 2000; 109:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coulston J, Balaratnam N. Irreversible sensorineural hearing loss due to clarithromycin. Postgrad Med J 2005; 81:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanoverschelde A, Oosterloo BC, Ly NF, et al. Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss. J Antimicrob Chemother 2021; 76:2708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson DJ, Sung RJ, Fine MJ, et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasquez EM, Maddux MS, Sanchez J, Pollak R. Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin. Arch Intern Med 1993; 153:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bizjak ED, Haug MT 3rd, Schilz RJ, et al. Intravenous azithromycin-induced ototoxicity. Pharmacotherapy 1999; 19:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajiioannou JK, Florou V, Kousoulis P, et al. Clarithromycin induced reversible sensorineural hearing loss. B-ENT 2011; 7:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergeron A, Chevret S, Granata A, et al. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. JAMA 2017; 318:557.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA warns about increased risk of cancer relapse with long-term use of azithromycin (Zithromax, Zmax) antibiotic after donor stem cell. https://www.fda.gov/Drugs/DrugSafety/ucm614085.htm (Accessed on April 24, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel B, Sheshadri A, Saliba RM, et al. Azithromycin Exposure Following Hematopoietic Stem Cell Transplantation Is Associated with an Increased Risk of Cancer Relapse in Acute Leukemia. Biol Blood Marrow Transplant 2019; 25:S231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng GS, Bondeelle L, Gooley T, et al. Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2020; 26:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamoun M. The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD). Biol Blood Marrow Transplant 2019; 25:S26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutzke JL, Merten JA, Taraba JL, et al. Risk of relapse in patients receiving azithromycin after allogeneic HSCT. Bone Marrow Transplant 2021; 56:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomason AR, Waldrop BA, Price SO. Nortriptyline cardiac toxicity from a probable interaction with telithromycin. Hosp Pharm 2009; 44:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strandell J, Bate A, Hägg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol 2009; 68:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns H, Russell L, Cox ZL. Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism. J Clin Pharm Ther 2021; 46:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill K, Sucha E, Rhodes E, et al. Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. JAMA Intern Med 2020; 180:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung IF, Wu AK, Cheng VC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41:291.
          </a>
         </li>
         <li class="breakAll">
          Colcrys. http://www.colcrys.com/ (Accessed on May 24, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 2013; 310:2544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajasekaran KK, Jeganathan J, Raghuram PM. Does Azithromycin and Cetirizine Combination Given for Upper Respiratory Tract Infections has any Significant Effect on QTc? J Clin Diagn Res 2017; 11:OC10.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 474 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1421677" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7849341" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1310839" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : New macrolide antibiotics: azithromycin and clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1330097" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Azithromycin: the first azalide antibiotic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32636299" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33332296" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15308279" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Macrolides and ketolides: azithromycin, clarithromycin, telithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Sexually Transmitted Infections Treatment Guidelines, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30881064" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32170033" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30885902" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Species Distribution and Macrolide Susceptibility of Mycobacterium fortuitum Complex Clinical Isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35453266" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment for Pseudomonas aeruginosa Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17292768" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27799212" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acquired clarithromycin resistance in disseminated Mycobacterium avium-intracellulare complex: Case report
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11797175" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9988052" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10524961" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21195981" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Distribution of genes encoding resistance to macrolides, lincosamides and streptogramins among clinical staphylococcal isolates in a Turkish university hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17846580" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Resistance to macrolide, lincosamide and streptogramin antibiotics in staphylococci isolated in Istanbul, Turkey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10223914" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26029831" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Macrolide-Resistant Pneumococcus in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26029831" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Macrolide-Resistant Pneumococcus in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30924986" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Management and clinical outcomes after lung transplantation in patients with pre-transplant Mycobacterium abscessus infection: A single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30689764" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mycobacterium abscessus and Antibiotic Resistance: Same As It Ever Was.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19805553" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Global challenge of antibiotic-resistant Treponema pallidum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230759" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14693524" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28116959" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696068" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Telithromycin new product overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lack of Effect of Food on the Bioavailability of Oral Azithromycin Tablets
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23357769" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1318761" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1312921" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clarithromycin and azithromycin: new macrolide antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1312921" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clarithromycin and azithromycin: new macrolide antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1312921" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clarithromycin and azithromycin: new macrolide antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10052544" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10052544" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16186790" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Azithromycin extended-release (Zmax) for sinusitis and pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32075790" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30779772" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33454317" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8008325" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9469269" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16734900" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pregnancy outcome following gestational exposure to azithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33568349" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11338912" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11338912" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11338912" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11338912" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25111234" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical and histologic features of azithromycin-induced liver injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9384342" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Azithromycin: a critical review of the first azilide antibiotic and its role in pediatric practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9384342" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Azithromycin: a critical review of the first azilide antibiotic and its role in pediatric practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17314341" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Clinical practice. Diabetic gastroparesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24631273" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Azithromycin: mechanisms of action and their relevance for clinical applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30675023" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Motilin: from gastric motility stimulation to hunger signalling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28279123" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A pioneering study: oral clarithromycin treatment for feeding intolerance in very low birth weight preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29353050" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12235254" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12065733" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23525864" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25139799" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10943628" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clarithromycin associated with torsades de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356306" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Oral erythromycin and the risk of sudden death from cardiac causes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26564594" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32463348" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33478708" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27150690" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27150690" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26903359" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23635046" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cardiovascular risks with azithromycin and other antibacterial drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25165550" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25602299" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25409476" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, andβ-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25494485" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Cardiac risks associated with antibiotics: azithromycin and levofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24615307" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32585019" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Association of Azithromycin Use With Cardiovascular Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Use of azithromycin and risk of ventricular arrhythmia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23635050" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Use of azithromycin and death from cardiovascular causes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24893087" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24827057" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Lack of association between azithromycin and death from cardiovascular causes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29610207" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33226983" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22591294" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Azithromycin and the risk of cardiovascular death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29614166" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Another Caution for Clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16339220" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26768836" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cardiovascular outcomes associated with use of clarithromycin: population based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29036565" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Long-Term Risk of Acute Myocardial Infarction, Stroke, and Death With Outpatient Use of Clarithromycin: A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28115334" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28115334" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28115334" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10778901" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15640431" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Irreversible sensorineural hearing loss due to clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34312676" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1731511" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8466379" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030778" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Intravenous azithromycin-induced ototoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21838098" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Clarithromycin induced reversible sensorineural hearing loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28787506" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28787506" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Azithromycin Exposure Following Hematopoietic Stem Cell Transplantation Is Associated with an Increased Risk of Cancer Relapse in Acute Leukemia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31682980" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33130820" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Risk of relapse in patients receiving azithromycin after allogeneic HSCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Nortriptyline cardiac toxicity from a probable interaction with telithromycin
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19740401" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33277702" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32511684" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16007523" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16007523" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24346990" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29207751" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Does Azithromycin and Cetirizine Combination Given for Upper Respiratory Tract Infections has any Significant Effect on QTc?
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
